The members of this area are high-level researchers, as evidenced by their high-impact publications and the leadership of several of the competitive projects in which they participate. The main objective of the groups that make up this area is to generate scientific knowledge in order to transmit it to students in the case of the university, and to improve healthcare practice in the case of the hospital. This results in a better quality of life and health for citizens.
PhD in Biochemistry and Molecular Biology (UAM), he trained as a researcher at the Severo Ochoa Centre of Molecular Biology, the Free University of Brussels, and the University of Leiden.
Since 1998 he has been working as a researcher in the Molecular Oncology Laboratory at the HCSC.
He is currently working on the characterisation of splicing in breast and ovarian cancer susceptibility genes, and the development of standardised variant classification criteria.
He has published more than 150 scientific articles and has been PI of 8 competitive projects (including the H2020-BRIDGES project).
Read moreHe is a member of: Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), ClinGEN ENIGMA BRCA1/2 Variant Curation Expert Panel, ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), GEICAM (Pephi working group), SOLTI-HOPE_Molecular Advisory Board, Cancer Predisposition Variant Interpretation Committee of the IMPACT-Genomics Project, and the HCSC Tumour Molecular Committee. He is also a member of the IdISSC research commission representing the Oncology area, and a member of the HCSC MTB.
He regularly lectures in national and international forums related to his speciality and is Professor in four Master’s programmes at UCM.
Complementary to his activity in the diagnostic laboratory, he has developed a translational research career focused on the genetic diagnosis of breast and ovarian cancer susceptibility conditions. So far, he has obtained 5 ISCIII grants and one EU-H2020 grant, all of them related to breast and ovarian cancer susceptibility, and variant interpretation.
He is (co-)author of more than 140 peer-reviewed articles on BC/OC genetic susceptibility. He is currently particularly interested in the impact that natural alternative splicing could have on the clinical classification of genetic variants in breast and ovarian cancer susceptibility genes. His articles have been cited 4745 times and his H index is currently 39.
